Apontis Pharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Bruno Wohlschlegel
Chief executive officer
€181.0k
Total compensation
| CEO salary percentage | 59.7% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 2.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | €181k | €108k | -€11m |
Compensation vs Market: Bruno's total compensation ($USD193.86K) is below average for companies of similar size in the German market ($USD433.43K).
Compensation vs Earnings: Insufficient data to compare Bruno's compensation with company performance.
CEO
Bruno Wohlschlegel (56 yo)
less than a year
Tenure
€180,964
Compensation
Mr. Bruno Wohlschlegel serves as Member of Management Board at Apontis Pharma AG since September 01, 2023 and served as its Chief Executive Officer since September 01, 2023 until 2024. He is Chairman of Ma...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Supervisory Board | no data | no data | no data | |
| Independent Deputy Chairman of Supervisory Board | 2.1yrs | no data | no data | |
| Independent Chairman of Supervisory Board | 2.1yrs | no data | no data | |
| Member of Supervisory Board | no data | no data | no data | |
| Member of Supervisory Board | 2.1yrs | no data | no data |
2.1yrs
Average Tenure
54yo
Average Age
Experienced Board: APPH's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.